Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy.
Antipsychotic monotherapy
Antipsychotic polypharmacy
Antipsychotics
Readmission rates
Journal
Community mental health journal
ISSN: 1573-2789
Titre abrégé: Community Ment Health J
Pays: United States
ID NLM: 0005735
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
13
06
2022
accepted:
22
09
2022
pubmed:
16
10
2022
medline:
7
3
2023
entrez:
15
10
2022
Statut:
ppublish
Résumé
Antipsychotic medications are used to treat many psychiatric conditions and are paramount for relapse prevention in patients with mental illnesses. Antipsychotic monotherapy (APM) is a commonly recommended approach, however there is no clear consensus on the use of antipsychotic polypharmacy (APP). A single-center retrospective review was conducted comparing readmission rates of behavioral health patients discharged on APP or APM between August 1st 2019 and July 31st 2021. The primary outcome was the one-year psychiatric readmission rate. Secondary outcomes included further readmission time frame stratification, olanzapine equivalent doses, and use of anticholinergic medications. The total readmission rate was 24.5% (24/98) in the APP group compared to 19.1% (107/560) in the APM group (p = 0.22). Patients discharged on APM were not found to have a statistically significant increase in readmission rate compared to patients discharged on APP. Further research is needed to assess the risks and benefits of APP.
Identifiants
pubmed: 36242684
doi: 10.1007/s10597-022-01034-5
pii: 10.1007/s10597-022-01034-5
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-511Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Baker, J., & Aebi, C. (2018). Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon. The mental health clinician, 7(3), 124–130. https://doi.org/10.9740/mhc.2017.05.124
doi: 10.9740/mhc.2017.05.124
pubmed: 29955510
pmcid: 6007569
Borlido, C., Remington, G., Graff-Guerrero, A., Arenovich, T., Hazra, M., Wong, A., Daskalakis, Z. J., & Mamo, D. C. (2016). Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 77(1), e14–e20. https://doi.org/10.4088/JCP.14m09321
doi: 10.4088/JCP.14m09321
pubmed: 26845273
Boskailo, E., Malkoc, A., McCurry, D. B., Venter, J., Drachman, D., & Ramos, G. M. (2017). Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study. Acta medica academica, 46(2), 133–144. https://doi.org/10.5644/ama2006-124.198
doi: 10.5644/ama2006-124.198
pubmed: 29338277
Carnahan, R. M., Lund, B. C., Perry, P. J., & Chrischilles, E. A. (2006). Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatrica Scandinavica, 113(2), 135–141. https://doi.org/10.1111/j.1600-0447.2005.00589.x
doi: 10.1111/j.1600-0447.2005.00589.x
pubmed: 16423165
Constantine, R. J., Andel, R., McPherson, M., & Tandon, R. (2015). The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophrenia research, 166(1–3), 194–200. https://doi.org/10.1016/j.schres.2015.05.038
doi: 10.1016/j.schres.2015.05.038
pubmed: 26141142
Coupland, C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA internal medicine, 179(8), 1084–1093. https://doi.org/10.1001/jamainternmed.2019.0677
doi: 10.1001/jamainternmed.2019.0677
pubmed: 31233095
pmcid: 6593623
Dazzan, P., Morgan, K. D., Orr, K., Hutchinson, G., Chitnis, X., Suckling, J., Fearon, P., McGuire, P. K., Mallett, R. M., Jones, P. B., Leff, J., & Murray, R. M. (2005). Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 30(4), 765–774. https://doi.org/10.1038/sj.npp.1300603
doi: 10.1038/sj.npp.1300603
pubmed: 15702141
Farrell, C., & Brink, J. (2020). The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample. Frontiers in psychiatry, 11, 263. https://doi.org/10.3389/fpsyt.2020.00263
doi: 10.3389/fpsyt.2020.00263
pubmed: 32528318
pmcid: 7247840
Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Schizophrenia research, 138(1),18–28. https://doi.org/10.1016/j.schres.2012.03.018
Gören, J. L., Parks, J. J., Ghinassi, F. A., Milton, C. G., Oldham, J. M., Hernandez, P., Chan, J., & Hermann, R. C. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission journal on quality and patient safety, 34(10), 571–582. https://doi.org/10.1016/s1553-7250(08)34072-0
doi: 10.1016/s1553-7250(08)34072-0
pubmed: 18947117
Hori, H., Yoshimura, R., Katsuki, A., Sugita, A. I., Atake, K., & Nakamura, J. (2013). Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of psychiatric research, 47(12), 1843–1848. https://doi.org/10.1016/j.jpsychires.2013.08.024
doi: 10.1016/j.jpsychires.2013.08.024
pubmed: 24054464
Kadra, G., Stewart, R., Shetty, H., MacCabe, J. H., Chang, C. K., Kesserwani, J., Taylor, D., & Hayes, R. D. (2018). Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology (Berl), 235(1), 281–289. https://doi.org/10.1007/s00213-017-4767-6
doi: 10.1007/s00213-017-4767-6
pubmed: 29080904
Leucht, S., Samara, M., Heres, S., & Davis, J. M. (2016). Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophrenia bulletin, 42 Suppl 1(Suppl 1), S90–S94. https://doi.org/10.1093/schbul/sbv167
Leucht, S., Samara, M., Heres, S., Patel, M. X., Furukawa, T., Cipriani, A., Geddes, J., & Davis, J. M. (2015). Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. Schizophrenia bulletin, 41(6), 1397–1402. https://doi.org/10.1093/schbul/sbv037
doi: 10.1093/schbul/sbv037
pubmed: 25841041
pmcid: 4601707
Lin, C. H., Wang, F. C., Lin, S. C., Huang, Y. H., & Chen, C. C. (2017). A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Schizophrenia research, 185, 80–87. https://doi.org/10.1016/j.schres.2017.01.004
doi: 10.1016/j.schres.2017.01.004
pubmed: 28109665
Smith, R. L., Tveito, M., Kyllesø, L., Jukic, M. M., Ingelman-Sundberg, M., Andreassen, O. A., & Molden, E. (2020). Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 37, 64–69. https://doi.org/10.1016/j.euroneuro.2020.06.007
doi: 10.1016/j.euroneuro.2020.06.007
pubmed: 32595082
Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019). Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA psychiatry, 76(5), 499–507. https://doi.org/10.1001/jamapsychiatry.2018.4320
doi: 10.1001/jamapsychiatry.2018.4320
pubmed: 30785608
pmcid: 6495354